延长抗生素治疗与胰十二指肠切除术后中高危患者临床相关胰瘘发生率降低相关:单中心分析
单中心分析87例接受择期胰十二指肠切除术、胰腺质地软且瘘风险评分≥3的患者,其中34例接受术后10天广谱抗生素(延长组),53例接受标准围术期抗生素(单次术前给药)。延长组临床相关术后胰瘘、切口感染、器官腔隙感染及影像引导下置管引流率均低于标准组,且无艰难梭菌感染。
要点
- 瘘风险评分≥3且胰腺质地软的患者术后延长抗生素10天,临床相关胰瘘发生率11.8% vs 37.7%(OR=0.17,95%CI 0.04-0.68)。
- 延长组切口感染8.8% vs 30.2%(OR=0.08,95%CI 0.01-0.50),器官腔隙感染14.7% vs 43.4%(OR=0.15,95%CI 0.04-0.52)。
- 延长组影像引导下置管引流率8.8% vs 34.0%(OR=0.15,95%CI 0.04-0.62),且无艰难梭菌感染。
核心结论
- 在瘘风险评分≥3的患者中,延长抗生素治疗与胰十二指肠切除术后临床相关术后胰瘘及相关并发症发生率降低相关。
研究设计与样本
- 单中心分析纳入2018年至2022年接受择期胰十二指肠切除术、胰腺质地软且瘘风险评分≥3的87例患者。
- 患者接受术后10天广谱抗生素(延长组,n=34)或标准围术期抗生素(单次术前给药,标准组,n=53)。
- 分析延长抗生素与术后结局之间的关联。
主要发现
- 两组基线临床人口学因素相似。
- 延长组住院天数6天 vs 标准组8天(P=0.004),90天复合住院时间8.5天 vs 12天(P=0.018)。
- 延长组临床相关术后胰瘘11.8% vs 37.7%(OR=0.17,95%CI 0.04-0.68)。
- 延长组切口感染8.8% vs 30.2%(OR=0.08,95%CI 0.01-0.50),器官腔隙感染14.7% vs 43.4%(OR=0.15,95%CI 0.04-0.52)。
- 延长组影像引导下置管引流8.8% vs 34.0%(OR=0.15,95%CI 0.04-0.62),延长组无艰难梭菌感染。
临床怎么用
- 本研究中心对临床相关术后胰瘘风险增加(瘘风险评分≥3)的患者实施了延长抗生素路径。
- 作者指出这些结果构成了随机对照试验(NCT05753735)的基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinically relevant postoperative pancreatic fistula remains a common complication after pancreatoduodenectomy. The fistula risk score is a validated tool to predict the risk of clinically relevant postoperative pancreatic fistula. To mitigate complications, we have implemented an extended antibiotic pathway for patients at increased risk of clinically relevant postoperative pancreatic fistula (fistula risk score ≥3). We report outcomes after pancreatoduodenectomy in patients at increased risk for clinically relevant postoperative pancreatic fistula who received extended antibiotic therapy compared to those who received standard perioperative antibiotics (single dose before incision). METHODS: Single-institution analysis of 87 patients who underwent elective pancreatoduodenectomy (2018-2022) with soft gland texture and fistula risk score ≥3 and were treated with (n = 34) or without (n = 53) 10 days of broad-spectrum antibiotics (piperacillin/tazobactam converted to amoxicillin/clavulanic acid at discharge) after surgery. Associations between extended antibiotics and postoperative outcomes were analyzed. RESULTS: Baseline clinicodemographic factors were similar between cohorts. Patients who received extended antibiotics had shorter index days (6 vs 8 days, P = .004) and 90-day composite length of stay (8.5 vs 12 days, P = .018). Patients who received extended antibiotics had lower rates of clinically relevant postoperative pancreatic fistula (11.8% vs 37.7%; odds ratio = 0.17, 95% confidence interval: 0.04-0.68), wound infections (8.8% vs 30.2%; odds ratio = 0.08, 95% confidence interval: 0.01-0.50), organ space infections (14.7% vs 43.4%; odds ratio = 0.15, 95% confidence interval: 0.04-0.52), and image-guided drain placement (8.8% vs 34.0%; odds ratio = 0.15, 95% confidence interval: 0.04-0.62). There were no Clostridium difficile infections in the extended antibiotic group. CONCLUSION: Extended antibiotic therapy is associated with a lower rate of clinically relevant postoperative pancreatic fistula and associated complications after pancreatoduodenectomy in patients with a fistula risk score ≥3. These results form the basis of a randomized controlled trial (NCT05753735).
引用
- Ocuin LM, Loftus A, Elshami M, et al. Extended antibiotic therapy is associated with a lower rate of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy in intermediate- and high-risk patients: A single-institution analysis. Surgery. 2023. PMID: 37940433. doi:10.1016/j.surg.2023.09.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。